Stroke, Ischemic, Stroke Sequelae
Conditions
Keywords
Stroke, Hypoxic conditioning, Intermittent hypoxia, Recovery, Biomarkers, Safety
Brief summary
By inducing endogenous neuroprotection, hypoxic post-conditioning following stroke may represent a harmless and efficient non-pharmacological innovative neuro-therapeutic modality aiming at inducing neuroplasticity and brain repair, as supported by many preclinical studies. The investigators thus hypothesize that hypoxic post-conditioning represents a safe therapeutic strategy post-stroke. The investigators further hypothesize that hypoxic conditioning could enhance neuroplasticity and function in combination with conventional rehabilitative care. The primary study endpoint will be safety. Safety will be assessed through the clinical review of the adverse events over the duration of the study, every 48 hours by a trained evaluator, blinded for the therapeutic intervention. The investigators will further investigate the potential functional benefits of such a therapeutic approach on motor function, gait, balance, and cognition. The neurophysiological substrates of hypoxic conditioning-triggered neuroplasticity at a subacute delay post-stroke will also be investigated, based on biological and imagery markers.
Detailed description
Stroke is the second leading cause of death and the third leading cause of disability-adjusted life-years worldwide. If acute stroke therapy has decreased mortality, more than 50% of stroke survivors are left with sensorimotor and cognitive deficiencies. Recovery and rehabilitation treatments, aiming at inducing neuroplasticity, maximizing function in unaffected brain areas or implementing compensatory strategies to improve overall function, benefit from an extensive time window that ranges from days to months. Their development is urgently needed. Several endogenous neuroprotective mechanisms are spontaneously engaged following stroke to achieve neuroprotection and stimulate brain repairing processes. Conditioning the central nervous system can trigger endogenous mechanisms of neuroprotection. Conditioning refers to a procedure by which a potentially deleterious stimulus is applied near to but below the threshold of damage to the organism. While hypoxia is well recognized as a common underlying mechanism of many pathological conditions, experimental data indicate that exposure to specific doses of hypoxia (by breathing a hypoxic gas mixture) can be neuroprotective. Preconditioning is defined as the exposure to the conditioning stimulus before injury onset, to induce tolerance or resistance to the subsequent injury. Postconditioning refers to the application of the conditioning stimulus after injury or damage, to stimulate tissue reparation or neuroplasticity. As stroke is an unpredictable event, translating hypoxic preconditioning to clinical practice seems difficult. However, developing postconditioning strategies seems of clinical and rehabilitative relevance. Thus, an increase in neuronal salvage and neurogenesis, along with an increase in brain-derived neurotrophic factor expression and a reduced neuroinflammation were shown in murine models of hypoxic conditioning following ischemic stroke. By inducing endogenous neuroprotection, hypoxic conditioning may represent a harmless and efficient non-pharmacological innovative neuro-therapeutic modality aiming at inducing neuroplasticity and brain repair, as supported by many preclinical studies. The main working hypothesis is that hypoxic postconditioning may represent a safe therapeutic strategy post-stroke. The investigators further hypothesize that hypoxic conditioning could enhance neuroplasticity and function in combination with conventional rehabilitative care. The primary study endpoint will be safety. Safety will be assessed through the clinical review of the adverse events over the duration of the study, every 48 hours by a trained evaluator, blinded for the therapeutic intervention. All adverse events will be evaluated and quoted in accordance with National Institute of Health Common Criteria for Terminology for Adverse Events 5.0 (NIH CCTAE) recommendations, particularly with respect to Sub-sections Cardiac disorders , Nervous system disorders and Vascular Disorders. Safety assessments will be performed every 48 hours, throughout the 8-week conditioning period, in addition to the conventional clinical follow-up performed in the rehabilitation unit. The potential functional benefits of such a therapeutic approach on motor function, gait, balance, and cognition will also be further investigated. The neurophysiological substrates of hypoxic conditioning-triggered neuroplasticity at a subacute delay post-stroke will be investigated, based on biological (serum inflammatory markers, growth and neurogenesis biomarkers) and imagery markers (morphological MRI sequences, functional connectivity (resting state), and brain vascularization).
Interventions
The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia. Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment. For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.
OTHERNormoxia
The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
Sponsors
Agir pour les maladies chroniques
University Hospital, Grenoble
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
The patients, as well as the experimenters performing the assessment sessions, will be blinded to the level of hypoxia. Only operators not involved in the monitoring of patients within the protocol and who will set the hypoxia generator device will not be concerned by the blind procedure.
Intervention model description
Phase I (safety and tolerability) clinical trial (impact on intermediate endpoints) evaluating a chronic (one month) hypoxic conditioning strategy for stroke, single-center, dose-escalation accelerated titration design (Liu S., Contemp. Clin. Trials. 2013) with continuous safety reassessment method. Dose escalation protocol. Dose escalation consisting of 4 successive steps, with increasing doses of hypoxia and continuous reassessment of safety criteria (primary endpoint, see below) Phase 2: Randomised, double-blind, controlled study comparing a group exposed to intermittent hypoxic post-conditioning versus a group exposed for the same duration and under the same conditions to a normoxic stimulus.
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients with minor cerebral infarction with NIHSS \< or equal to 5 will be included in the protocol; * Cerebral infarction occurring one month (±1 week) before the planned start of hypoxic exposure; * Age ≥18 years; * A first, unilateral, ischemic, supra-tentorial hemispheric stroke, confirmed by magnetic resonance imaging; * Modified Rankin Scale score between 1 and 3, defining mild to moderate residual functional disability. * A person affiliated with the social security system or benefits from such a system; * A person who has given written informed consent.
Exclusion criteria
* Patients who are minors or over 85 years of age, pregnant or breastfeeding women, or women of childbearing potential in the absence of highly effective contraception; * Stroke of the brainstem or cerebellum ; * Severe aphasia, limiting the ability to understand the protocol; * History of central or peripheral neurological pathology; * Modified Rankin Scale score \>0 before stroke; * Known severe untreated obstructive sleep apnea syndrome, defined as an apnea-hypopnea index ≥ 30 events per hour of sleep; * Pre-existing hypoxemic lung disease (such as chronic obstructive pulmonary disease); * Heart failure, defined as an ejection fraction ≤40% ; * History of high altitude pathology; * Scheduled stay at altitude (\> 2500 m) during the study period ; * Migraine; * History of rheumatological or orthopedic disease of the lower limbs, amputation of the lower limb. * Contraindication to magnetic resonance imaging; * Subjects who cannot be contacted in an emergency; * Subject in exclusion period of another study; * Subject under administrative or judicial supervision; * Persons referred to in Articles L1121-5 to L1121-8 of the Code de la Santé Publique (corresponds to all protected persons: pregnant women, women in labor, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Secondary adverse events | Through study completion, an average of 8 weeks | The safety of such a therapeutic strategy will be assessed by systematic screening for adverse events at each conditioning session and at follow-up visits throughout the duration of exposure (8 weeks) by a trained experimenter, blinded to the therapeutic intervention. All adverse events will be assessed and scored as a composite endpoint according to the NIH CCTAE 5.0 (National Institute of Health Common Terminology Criteria for Adverse Events), including in particular those listed in the sub-sections on Cardiological Pathologies, Central Nervous System Pathologies and Vascular Pathologies. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Barthel index | Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months | Activity limitation - Barthel index Score range: 0-100 The higher the score, the better the function and the independence |
| Magnetic resonance imagery - Diffusion and perfusion sequences | Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months | The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. Bolus perfusion (gadolinium) T1 and Diffusion Tensor Imaging (DTI, 60 directions or High Angular Resolution Diffusion Imaging (HARDI)), allowing calculation of the Apparent Diffusion Coefficient (ADC) map. |
| Magnetic resonance imagery - Cerebral blood flow | Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months | The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. Cerebral vasoreactivity (to a hypercapnic stimulus) assessed by Arterial Spin Labelling (ASL) and Blood oxygenation level-dependent (BOLD) sequences. |
| Magnetic resonance imagery - Resting state functional magnetic resonance imaging (fMRI) | Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months | The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. Functional connectivity measurements. |
| Cerebral Blood Flow | Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months | Cerebral blood flow will be assessed by measuring the flow velocity in the middle cerebral artery (MCAv), estimated by continuous measurement of the right middle cerebral artery using a 2 megahertz (MHz) pulsed transcranial Doppler (TCD) (MultiDop T, Compumedics Germany GmbH, Germany). Following standardized research techniques, the Doppler probe will be fixed to the temporal window with the aid of a helmet (DiaMon, Compumedics Germany GmbH) to maintain an optimal insonation position throughout the study and thus avoid any movement artifact. |
| Fugl-Meyer | Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months | Function - Fugl-Meyer motor function Score range: 0-100 Higher values indicate better performance. A score of 96-99 indicates light motor incoordination A score of 85-95 indicates hemiparesis A score ≤ 84 indicates hemiplegia |
| New Functional ambulation category (nFAC) score | Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months | Function - New Functional ambulation category (nFAC) score Score range: 0-5 A score of 0 indicates no functional ability to walk A score of 5 indicates independent walking |
| Prospective collection of number of falls | Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months | Function - Prospective collection of number of falls |
| Modified Rankin Scale (mRS) | Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months | Activity limitation - Modified Rankin Scale (mRS) Score range: 0-6 The mRS scores range from à (no symptom) to 6 (death) |
| Timed-up and Go test | Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months | Mobility - Timed-up and Go test: 3 trials |
| 16-item Stroke Impact Scale | Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months | Participation The higher the score, the better the performance. |
| 10-metre walk test | Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months | Mobility - Instrumented 10-metre walk test, carried out at spontaneous walking speed, 3 trials: collection of quantitative spatiotemporal step parameters and their variability, collection of walking speed. |
| Montreal Cognitive Assessment | Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months | Neuropsychological assessment Score range: 0-30 Normal if \>26/30 The higher the score, the better the cognitive performance. |
| Magnetic resonance imagery - Morphological sequences | Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months | The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. High-resolution anatomical sequences: T1, T2, FLAIR, for calculation of lesion volume and delineation of lesion mask. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Biomarkers of hypoxic conditioning - Erythropoietin (EPO) | Phase 2: Inclusion, 2 months, 6 months | Phase 2 only. A blood sample collection will be performed to secondary assess the Erythropoietin (EPO) levels in the serum. Unit: milli-international unit/mL |
| Biomarkers of hypoxic conditioning - Hypoxia inducible factor 1 | Phase 2: Inclusion, 2 months, 6 months | Phase 2 only. A blood sample collection will be performed to secondary assess the Hypoxia inducible factor 1 levels in the blood. Analytic method: RNA extraction Unit: Normalised copy number |
| Biomarkers of hypoxic conditioning - Vascular Endothelial Growth Factor (VEGF) | Phase 2: Inclusion, 2 months, 6 months | Phase 2 only. A blood sample collection will be performed to secondary assess the VEGF levels in the blood. Analytic method: ELISA |
| Biomarkers of hypoxic conditioning - Brain Derived Neurotrophic Factor (BDNF) | Phase 2: Inclusion, 2 months, 6 months | Phase 2 only. A blood sample collection will be performed to secondary assess the Brain-Derived Neurotrophic Factor (BDNF) levels in the serum. Unit: pg/ml |
Countries
France
Outcome results
None listed